In clinical studies and biostatistical analysis, Time-to-Event refers to the time interval from a defined starting point until the occurrence of a specific event. The term is used to describe endpoints that are not single measurements but rather time points or durations. Common events include death, progression, recurrence, hospitalization, treatment failure, or discontinuation of treatment.
Time-to-event endpoints are particularly valuable because they consider both whether an event occurs and when it occurs. This allows for a nuanced assessment of therapies, for example, whether they delay an event. This plays a significant role in regulatory approval programs, such as for Progression-Free Survival, Time to Treatment Failure, or Time to First Exacerbation. For sponsors and CROs, this leads to specific requirements for follow-up, event confirmation, and robust data management, as unclear time points or missing follow-up directly distort estimates.
Definition of Starting Point, Event, and Measurement Rules
For a time-to-event endpoint to be robust, the starting point, event definition, and rules for censoring must be clearly described in the study protocol. Randomization or first dose are often chosen as starting points to reduce selection and lead-time bias. Events must be operationalized, for example, according to RECIST criteria for tumor progression or predefined clinical criteria for exacerbations. In medical device studies, the definition of a device failure is important, e.g., revision, replacement, or loss of function.
A common error is inconsistent event assessment across study sites. Central reviews, training, and clear documentation in Standard Operating Procedures can help. It should also be determined which data sources are prioritized for event times (e.g., imaging, laboratory values, physician’s letters, registry data) and how to handle conflicting information. For composite endpoints, it must additionally be described which event components count and how the earliest event is determined.
The precise definition of visit windows is also practically important: if endpoints are only collected at visits (e.g., imaging every 8 weeks), interval censoring or indirect estimates of the event time occur. Such effects should be considered in the endpoint definition and comprehensibly described in the Statistical Analysis Plan.
Censoring, Follow-up, and Data Quality
In time-to-event data, censoring is the norm: not every person experiences the event during the observation period. Study discontinuation, lost-to-follow-up, or study end lead to censored observations. Censoring is statistically unproblematic only if it is non-informative, i.e., independent of the actual risk for the event. In practice, it should therefore be examined whether discontinuations systematically vary between groups and whether certain reasons for discontinuation (e.g., lack of efficacy, adverse events) suggest informative censoring.
For data management, consistent date recording, plausibility checks, and a clean audit trail are central. Timelines should be documented from primary sources whenever possible. For decentralized studies or when using routine data, data sources, update cycles, validation, and their representation in the data model must be defined early. Additionally, it should be considered that subsequent therapies, rescue medication, or cross-over can influence the interpretation of time-to-event endpoints and should be addressed in sensitivity analyses.
From an operational perspective, it is worthwhile to manage critical events via an event workflow: clear responsibilities at the study site, prompt document requests, and a clear definition of when an event is considered confirmed. This reduces the risk of events entering the database late or inconsistently.
Analysis Approaches, Interpretation, and Reporting
Analysis is typically performed within the framework of survival analysis. The Kaplan-Meier curve visualizes event-free survival over time, and the Log-Rank test compares groups. Models such as the Cox Proportional Hazards model provide a Hazard Ratio as a measure of the relative treatment effect. Additionally, median times, event rates at fixed time points, or Restricted Mean Survival Time are reported.
It is important that key figures match the clinical question. Median times are easily communicable but can be unstable with short follow-up. A Hazard Ratio assumes proportional hazards; if this assumption is violated, alternative models or time-dependent effects should be considered. For interpretation, it is recommended to combine relative measures (Hazard Ratio) with absolute information (curve progression, event numbers, number at risk). The report should also transparently present definitions, censoring rules, and sensitivity analyses.
Study Design, Sample Size, and Event-Driven Logic
Time-to-event endpoints influence study design because statistical power, in many cases, primarily depends on the number of events rather than solely on the number of participants. Planning requires assumptions about event rates, recruitment duration, follow-up, and drop-out rates. In multicenter studies, a realistic recruitment model is crucial to achieve the required number of events.
For interim analyses, event-driven designs, or adaptive designs, control of the alpha error and documentation of decision rules must be ensured. Operationally, clear processes are needed to capture and verify events in a timely manner, ensuring that data cut-offs are correct and reproducible. The interfaces between the clinical team, biometrics, and data management should also be defined, e.g., who confirms events and when a case is considered final.
FAQ
Is Time-to-Event the same as Survival?
Survival is a specific time-to-event endpoint where the event is usually death. Time-to-Event is the overarching term and can refer to many types of events.
Why are Time-to-Event endpoints often event-driven?
Because the validity and power primarily depend on the number of observed events. Studies often run until a predefined number of events is reached.
What are typical problems with Time-to-Event data?
Inconsistent event definitions, informative censoring due to differing discontinuation rates, inaccurate date information, and biases from subsequent therapies or cross-over.
Regulatory References (Selection)
- Regulation (EU) No 536/2014 (Clinical Trials Regulation)
- ICH E6(R3): Good Clinical Practice
- ICH E9: Statistical Principles for Clinical Trials